Adams et al., 1993 - Google Patents
Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erb B-2 single-chain FvAdams et al., 1993
View PDF- Document ID
- 14520474986633359930
- Author
- Adams G
- McCartney J
- Tai M
- Oppermann H
- Huston J
- Stafford III W
- Bookman M
- Fand I
- Houston L
- Weiner L
- Publication year
- Publication venue
- Cancer Research
External Links
Snippet
The in vivo properties of monovalent and divalent single-chain Fv (sFv)-based molecules with the specificity of the anti-c-erbB-2 monoclonal antibody 741F8 were examined in scid mice bearing SK-OV-3 tumor xenografts. 741F8 sFv monomers exhibited rapid, biphasic …
- 206010028980 Neoplasm 0 title abstract description 131
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody
- A61K51/1003—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody not used, see subgroups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48369—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment
- A61K47/48507—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment the modifying agent being a well defined antibody or immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Adams et al. | Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erb B-2 single-chain Fv | |
| US20180155449A1 (en) | Covalent disulfide-linked diabodies and uses thereof | |
| KR102011549B1 (en) | Antigens associated with inflammatory bowel disease | |
| JPH09505737A (en) | Antibody against carcinoembryonic antigen (CEA) | |
| US20110091460A1 (en) | Receptor-targeting reagents | |
| Choi et al. | Biodistribution of 18F-and 125I-labeled anti-Tac disulfide-stabilized Fv fragments in nude mice with interleukin 2α receptor-positive tumor xenografts | |
| KR20200143366A (en) | Modified antibodies and radioactive metal labeled antibodies | |
| ES2361743T3 (en) | RECOGNITION OF THE TUMOR VASCULATURE AS A TARGET THROUGH THE RADIOMARKED ANTIBODY L19 DIRECTED AGAINST THE ED-B DOMAIN OF FIBRONECTINE. | |
| Kim et al. | Chemical modification to reduce renal uptake of disulfide-bonded variable region fragment of anti-Tac monoclonal antibody labeled with 99mTc | |
| Kim et al. | Lowering of pI by acylation improves the renal uptake of 99mTc-labeled anti-Tac dsFv: effect of different acylating reagents | |
| US9989524B2 (en) | Immuno imaging agent for use with antibody-drug conjugate therapy | |
| Pavlinkova et al. | Pharmacokinetics and biodistribution of a light-chain-shuffled CC49 single-chain Fv antibody construct | |
| Weiner et al. | Enhanced tumor specificity of 741F8-1 (sFv′) 2, an anti-c-erbB-2 single-chain Fv dimer, mediated by stable radioiodine conjugation | |
| Adams et al. | Optimization of in vivo tumor targeting in SCID mice with divalent forms of 741F8 anti-c-erbB-2 single-chain Fv: effects of dose escalation and repeated iv administration | |
| Kim et al. | Improved renal clearance and tumor targeting of 99mTc-labeled anti-Tac monoclonal antibody Fab by chemical modifications | |
| Carrasquillo et al. | Aminosyn II effectively blocks renal uptake of 18F-labeled anti-tac disulfide-stabilized Fv | |
| Huston et al. | Tumor targeting in a murine tumor xenograft model with the (sFv′) 2 divalent form of anti-c-erb B-2 single-chain Fv | |
| Boskovitz et al. | Human/murine chimeric 81C6 F (ab′) 2 fragment: preclinical evaluation of a potential construct for the targeted radiotherapy of malignant glioma | |
| AU2014213687B2 (en) | Immuno imaging agent for use with antibody-drug conjugate therapy | |
| Demignot et al. | Comparison of biodistribution of 791T/36 monoclonal antibody and its Fab/c fragment in BALB/c mice and nude mice bearing human tumor xenografts | |
| US9844607B2 (en) | Immuno imaging agent for use with antibody-drug conjugate therapy | |
| US20230390425A1 (en) | Radioactive complexes of anti-her2 antibody, and radiopharmaceutical | |
| Khawli et al. | Improving the chemotherapeutic index of IUdR using a vasoactive immunoconjugate | |
| Kobayashi et al. | Epitope Blocking: Positive and Negative Effects on the Biodistribution of 125I‐Labeled Anti‐Tac Disulfide‐stabilized Fv Fragment of Two Antibodies against Different Epitopes of the Circulating Antigen | |
| AU2014214997A1 (en) | Immuno imaging agent for use with antibody-drug conjugate therapy |